We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Issues | European Heart Journal | Oxford Academic Skip to Main Content

Focus Issue on Coronar Artery Disease

Issue @ A Glance

CardioPulse

Current Opinion

Review

Novel therapeutic concepts

Clinical Research

Coronary artery disease

Editorial

Coronary artery disease

Editorial

EHJ Brief Communication

Acute coronary syndromes

Basic Science

Prevention and epidemiology

Stratification for coronary events among patients with coronary artery disease is of considerable interest because of the potential to guide secondary preventive therapies. Our study proofs, that circulating miRNAs have the potential to improve risk stratification for secondary clinical events. In the future, these findings may result in risk stratification tools based on the prognostic value of miRNAs.

Editorial

Cardiovascular Flashlights

  • CME
  • Cover Image

    Cover Image

    issue cover

    Coronary microcirculatory pathophysiology: can we afford it to remain a black box?

    Axel R. Pries1,2* and Bettina Reglin1

    1Department of Physiology, Center for Cardiovascular Research, Charité, Charitéplatz 1, D-10117 Berlin, Germany; and 2Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany

    *Corresponding author. Tel: +49 30 450 570 521, Fax: +49 30 450 570 952, Email: axel.pries@charite.de

    Coronary microvascular networks play the key role in determining blood flow distribution in the heart. Matching local blood supply to tissue metabolic demand entails continuous adaptation of coronary vessels via regulation of smooth muscle tone and structural dilated vessel diameter. The importance of coronary microcirculation for relevant pathological conditions including angina in patients with normal or near-normal coronary angiograms [microvascular angina (MVA)] and heart failure with preserved ejection fraction (HFpEF) is increasingly recognized. For MVA, clinical studies have shown a prevalence of up to 40% in patients with suspected coronary artery disease and a relevant impact on adverse cardiovascular events including cardiac death, stroke, and heart failure. Despite a continuously increasing number of corresponding clinical studies, the knowledge on pathophysiological cause–effect relations involving coronary microcirculation is, however, still very limited. A number of pathophysiological hypotheses for MVA and HFpEF have been suggested but are not established to a degree, which would allow definition of nosological entities, stratification of affected patients, or development of effective therapeutic strategies. This may be related to a steep decline in experimental (animal) pathophysiological studies in this area during the last 15 years. Since technology to experimentally investigate microvascular pathophysiology in the beating heart is increasingly, in principle, available, a concerted effort to build ‘coronary microcirculatory observatories’ to close this gap and to accelerate clinical progress in this area is suggested.

    See figure legend on page 483.

  • Front Matter
  • Table of Contents
This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now